Search Result

Isoforms Recommended:	CDK4

Results for "

CDK4

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) AAK1 (2) ADC Cytotoxin (1) Akt (1) AMPK (1) Androgen Receptor (1) Antibiotic (1) Apoptosis (33) Aurora Kinase (1) Autophagy (6) Bcl-2 Family (2) Bcr-Abl (1) c-Met/HGFR (1) c-Myc (3) CaMK (1) Casein Kinase (1) Caspase (2) CDK (150) COX (1) CXCR (2) Cyclin G-associated Kinase (GAK) (2) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (1) Drug Metabolite (2) E1/E2/E3 Enzyme (1) E3 Ligase Ligand-Linker Conjugates (1) EGFR (3) Epigenetic Reader Domain (1) ERK (1) Estrogen Receptor/ERR (1) Ferroptosis (2) FGFR (1) FLT3 (4) Fungal (2) Glutathione Peroxidase (1) GSK-3 (6) HDAC (2) HIV (2) HSP (2) Isotope-Labeled Compounds (3) JAK (2) Ligands for Target Protein for PROTAC (4) LIM Kinase (LIMK) (3) MAP4K (1) MAPKAPK2 (MK2) (1) MDM-2/p53 (2) MEK (2) Mixed Lineage Kinase (2) Molecular Glues (3) NF-κB (1) p38 MAPK (1) PARP (1) PDGFR (1) Phosphatase (1) PI3K (2) Pim (1) PKC (3) PROTACs (14) Raf (1) RIP kinase (2) Salt-inducible Kinase (SIK) (3) Ser/Thr Protease (1) SHP2 (1) Small Interfering RNA (siRNA) (3) TAM Receptor (1) Tie (1) ULK (2) VEGFR (1) Wee1 (1)
By Research Areas:	Cancer (164) Infection (2) Inflammation/Immunology (4) Metabolic Disease (1) Neurological Disease (4)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Pre-designed siRNA Sets (3) siRNAs (3)

174

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-163640

CDK4 degrader 1	Molecular Glues CDK	Cancer
CDK4 degrader 1 (ML 1–71) is a molecular glue degrader that targets CDK4 .

HY-RS02381

CDK4 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CDK	Others
CDK4 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDK4 Human Pre-designed siRNA Set A CDK4 Human Pre-designed siRNA Set A

HY-RS02382

Cdk4 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CDK	Others
Cdk4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdk4 Mouse Pre-designed siRNA Set A Cdk4 Mouse Pre-designed siRNA Set A

HY-RS02383

CDK4 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CDK	Others
CDK4 Rat Pre-designed siRNA Set A contains three designed siRNAs for CDK4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDK4 Rat Pre-designed siRNA Set A CDK4 Rat Pre-designed siRNA Set A

HY-153443

CDK4-IN-2	CDK	Cancer
CDK4-IN-2 (A17) is a *CDK4* inhibitor, with K_i and IC₅₀ values of <10 nM. Used in cancer research .

HY-151898

CDK4/6-IN-14	CDK	Cancer
CDK4/6-IN-14 is a potent and highly selective *CDK4* and *CDK6* (CDK) inhibitor with IC₅₀s of 10 nM and 16 nM, respectively. CDK4/6-IN-14 exhibits more than 60-fold selectivity over CDKs 1, 2, 7, and 9, and shows high selectivity among other 205 kinases .

HY-153088

CDK4/6-IN-16	CDK	Cancer
CDK4/6-IN-16 (example 195) is a potent *CDK4* and *CDK6* inhibitor, with an IC₅₀ of 0.013 μM for *CDK4. CDK4/6-IN-16 can be used for the research of CDK4*-mediated disorders, such as cancer .

HY-146213

CDK4/6-IN-12	CDK	Cancer
CDK4/6-IN-12 is a potent cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. CDK4/6-IN-12 has enzymatic inhibitory activity for CDK4 and CDK6 with IC₅₀ of 592.3 nM and 3090 nM, respectively. CDK4/6-IN-12 can be used for the research of cancer .

HY-164376

CDK4/6-IN-21	CDK	Cancer
CDK4/6-IN-21 (compound I-52) is a *CDK4/6* inhibitor with IC₅₀ values of 3.88 and 3.31 nM for CDK4 and CDK6, respectively. CDK4/6-IN-21 has antitumor activity .

HY-164376A

CDK4/6-IN-21 maleate	CDK	Cancer
CDK4/6-IN-21 maleate (compound I-52) is a *CDK4/6* inhibitor with IC₅₀ values of 3.88 and 3.31 nM for CDK4 and CDK6, respectively. CDK4/6-IN-21 maleate has antitumor activity .

HY-126244

CDK4/6-IN-3	CDK	Cancer
CDK4/6-IN-3 is a brain-penetrant *CDK4/CDK6* inhibitor with K_is of <0.3 nM and 2.2 nM, respectively. CDK4/6-IN-3 inhibits CDK1 with a K_i of 110 nM. CDK4/6-IN-3 can be used for the treatment of glioblastoma .

HY-115993

CDK4/6-IN-10	CDK Apoptosis	Cancer
CDK4/6-IN-10 is a potent, selective and orally active *CDK4* and *CDK6* inhibitor with IC₅₀s of 22 nM and 10 nM, respectively. CDK4/6-IN-10 shows antitumor activity. CDK4/6-IN-10 has the potential for the research of Multiple myeloma (MM) .

HY-112418

CDK4/6-IN-18	CDK	Cancer
CDK4/6-IN-18 (Example 2BrIC) is a selective *CDK4/6* inhibitor. CDK4/6-IN-18 inhibits ionizing radiation (IR)-induced DNA damage in cells .

HY-161978

CDK4/6-IN-22	CDK	Cancer
CDK4/6-IN-22 (Compound 1-A) is a *CDK4* and *CDK6* dual inhibitor .

HY-114339

CDK4/6-IN-2	CDK	Cancer
CDK4/6-IN-2 is a potent *CDK4* and *CDK6* inhibitor extracted from patent US20180000819A1, Compound 1, has IC₅₀s of 2.7 and 16 nM for CDK4 and CDK6, respectively .

HY-139449

CDK4/6-IN-5	CDK	Cancer
CDK4/6-IN-5 is a potent *CDK4* and *CDK6* inhibitor with K_is of 0.2 and 4.4 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively . (from patent WO2019207463A1 example A93).

HY-162529

CDK4/6-IN-19	CDK	Cancer
CDK4/6-IN-19 (Compound II-7) is a *CDK4/CDK6* inhibitor with IC₅₀ values of 0.2, 5.0 nM, respectively. CDK4/6-IN-19 also inhibits cell proliferation and can be used in cancer research .

HY-162530

CDK4/6-IN-20	CDK	Cancer
CDK4/6-IN-20 (Compound II-5) is a *CDK4/CDK6* inhibitor with IC₅₀ values of 1.9, 14.2 nM, respectively. CDK4/6-IN-20 also inhibits cell proliferation and can be used in cancer research .

HY-143257

CDK4/6-IN-7	CDK	Cancer
CDK4/6-IN-7 is a potent, selective and orally active *CDK4/6* inhibitor, with IC₅₀s of 1.58 and 4.09 nM, respectively. CDK4/6-IN-7 can be used for the research of breast cancer .

HY-115992

CDK4/6-IN-9	CDK	Cancer
CDK4/6-IN-9 (compound 10) is a selective *CDK4/6* inhibitor with an IC₅₀ of 905 nM for CDK6/cyclin D1. CDK4/6-IN-9 has the potential for multiple myeloma (MM) research .

HY-153704

CDK4/6-IN-17	CDK	Cancer
CDK4/6-IN-17 (compound 12) is an orally active *CDK4/6* inhibitor with IC₅₀ ranging of 10-100 nM in BE(2) cells. CDK4/6-IN-17 inhibits tumor growth in COLO205 xenograft model .

HY-112280

Crozbaciclib CDK4/6/1 Inhibitor	CDK	Cancer
Crozbaciclib (CDK4/6/1 Inhibitor) is a *CDK4/6* inhibitor with IC₅₀s of 3 and 1 nM, respectively.

HY-142076

CDK4/6-IN-15	CDK	Cancer
CDK4/6-IN-15 is an orally active and selective *CDK4/6* inhibitor. CDK4/6-IN-15 potently inhibits cancer cells growth. CDK4/6-IN-15 arrests cell cycle at G1 phase and suppresses retinoblastoma tumour suppressor protein (Rb) phosphorylation at S780 and E2 factor (E2F)-regulated gene expression .

HY-142076A

CDK4/6-IN-15 hydrochloride	CDK	Cancer
CDK4/6-IN-15 hydrochloride is an orally active and selective *CDK4/6* inhibitor. CDK4/6-IN-15 hydrochloride potently inhibits cancer cells growth. CDK4/6-IN-15 hydrochloride arrests cell cycle at G1 phase and suppresses retinoblastoma tumour suppressor protein (Rb) phosphorylation at S780 and E2 factor (E2F)-regulated gene expression .

HY-143258

CDK4/6-IN-8	CDK	Cancer
CDK4/6-IN-8 (Compound 7p) is a selective *CDK4* and *CDK6* inhibitor with IC₅₀ values of 5.01 nM and 3.97 nM, respectively .

HY-170651

CDK4/6/HDAC-IN-1	CDK HDAC Apoptosis	Cancer
CDK4/6/HDAC-IN-1 (Compound N14) is a dual-targeting inhibitor of *CDK4/6* and HDAC (IC₅₀: CDK4 = 7.23 nM, CDK6 = 13.20 nM, HDAC1 = 55.66 nM, HDAC6 = 48.38 nM). CDK4/6/HDAC-IN-1 induces cell Apoptosis and G0/G1 phase arrest through *HDAC-p21-CDK* signaling pathway. CDK4/6/HDAC-IN-1 inhibits hepatocellular carcinoma .

HY-146214

CDK4/6-IN-13	CDK	Cancer
As a cdk4/6 inhibitor. Compounds 10B and 10C showed low nanomolar activity, ideal antiproliferative activity, excellent metabolic properties and acceptable pharmacokinetics on cdk4/6.

HY-15612

CDK4-IN-1	CDK	Cancer
CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50=5.265 uM) respectively.

HY-139450

Atirmociclib PF-07220060; CDK4/6-IN-6	CDK	Cancer
Atirmociclib (PF-07220060; example A94) is a potent *CDK4/CDK6* inhibitor with a K_i of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively .

HY-144995

BSJ-02-162 CDK4/6-IN-11	PROTACs CDK	Cancer
CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader . CDK4/6-IN-11 consists of a thalidomide-based E3 ligase ligand (blue part) Thalidomide-NH-CH2-COOH (HY-131717), a target protein ligand (red part) Palbociclib (HY-50767), and a PROTAC linker (black part) Boc-NH-C4-Br (HY-W007803). E3 ligase ligand and linker can form Thalidomide-NH-amido-C4-Br (HY-170307).

HY-115904

*FLT3/CDK4-IN-1*	CDK FLT3	Cancer
FLT3/CDK4-IN-1 is a potent, high selective and orally active *FLT3/CDK4* dual inhibitor (IC₅₀=11 and 7 nM for FLT3 and CDK4, respectively). FLT3/CDK4-IN-1 has antiproliferative activities against certain cancer cells. FLT3/CDK4-IN-1 has good antitumor effect in vivo .

HY-150609

*SHP2/CDK4-IN-1*	SHP2 Phosphatase CDK	Cancer
SHP2/CDK4-IN-1 (compound 10) is an orally active and potent SHP2 and *CDK4* dual inhibitor, with IC₅₀ values of 4.3 and 18.2 nM, respectively. SHP2/CDK4-IN-1 effectively induces G0/G1 arrest to prevent the proliferation of TNBC cell lines. SHP2/CDK4-IN-1 shows significant antitumor efficacy in the EMT6 syngeneic mouse model. SHP2/CDK4-IN-1 can be used for triple-negative breast cancer (TNBC) research .

HY-152263

*HEMTAC CDK4/6 degrader 1*	PROTACs CDK Apoptosis	Cancer
HEMTAC CDK4/6 degrader 1 is a PROTAC connected by ligands for HSP90 and *CDK4/6* with a K_d value of 35.7 μM. HEMTAC CDK4/6 degrader 1 induces CDK4/6 degradation in B16F10 melanoma cells. HEMTAC CDK4/6 degrader 1 arrests cell cycle at G0/G1 phase and induces apoptosis. HEMTAC CDK4/6 degrader 1 can be used in research of cancer . HEMTAC CDK4/6 degrader 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-138946

XY028-140	CDK PROTACs	Cancer
XY028-140 is a PROTAC connected by ligands for Cereblon and *CDK. XY028-140 inhibits both CDK4/6 expression and CDK4*/6 activity in cancer cells .

HY-163786

*PROTAC CDK4/6 degrader 1*	PROTACs CDK Apoptosis	Cancer
PROTAC CDK4/6 degrader 1 (Compound 7f) is a dual degrader for *CDK4* and *CDK6* with DC₅₀ of 10.5 and 2.5 nM. PROTAC CDK4/6 degrader 1 inhibits the proliferation of cell Jurkat (IC₅₀ is 0.18 μM), arrests the cell cycle at G1 phase and induces apoptosis. (Pink: ligand for target protein YY173 (HY-163787); Black: linker (HY-163788); Blue: ligand for E3 ligase (HY-10984))

HY-137449

Rintodestrant G1T48	Estrogen Receptor/ERR CDK	Cancer
Rintodestrant (G1T48) is an orally active, non-steroidal and selective estrogen receptor degrader. Rintodestrant (G1T48) is also a *CDK4/6* inhibitor .

HY-103380

NSC 625987 1 Publications Verification	CDK	Cancer
NSC 625987 is a specific and high-affinity *CDK4* inhibitor with an IC₅₀ of 0.2 μM for CDK4:cyclin D1. NSC 625987 shows >500-fold selectivity for CDK4 over CDK2 .

HY-169048

CDK2/4-IN-2	CDK	Cancer
CDK2/4-IN-2 (compound 56) is a *CDK2* and *CDK4* dual inhibitor with IC₅₀s less than 100 nM. CDK2/4-IN-2 can be used in the study of cancer .

HY-16297A

Abemaciclib 85+ Cited Publications LY2835219	CDK	Cancer
Abemaciclib (LY2835219) is a selective *CDK4/6* inhibitor with IC₅₀ values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-129180

XY028-133	PROTACs CDK	Cancer
XY028-133 (example 14) is a PROTAC-based *CDK4/6* degrader with anti-tumor activity, which consists of ligands for von Hippel-Lindau and *CDK* .

HY-112272A

Lerociclib dihydrochloride 1 Publications Verification G1T38 dihydrochloride	CDK	Cancer
Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective inhibitor of *CDK4/CDK6*, with IC₅₀s of 1 nM and 2 nM for *CDK4/CyclinD1* and *CDK6/CyclinD3*, respectively.

HY-16297

Abemaciclib methanesulfonate 85+ Cited Publications LY2835219 methanesulfonate	CDK	Cancer
Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective *CDK4/6* inhibitor with IC₅₀s of 2 nM and 10 nM for CDK4 and CDK6, respectively .

HY-16297AS

Abemaciclib-d8 LY2835219-d₈	CDK	Cancer
Abemaciclib-d₈ is the deuterium labeled Abemaciclib. Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-112272

Lerociclib 1 Publications Verification G1T38	CDK	Cancer
Lerociclib (G1T38) is a potent and selective inhibitor of *CDK4/6, with IC₅₀s* of 1 nM, 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively.

HY-50767S

Palbociclib-d8 PD 0332991-d₈	Isotope-Labeled Compounds CDK	Cancer
Palbociclib-d₈ is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].

HY-156646

Tibremciclib	CDK	Cancer
Tibremciclib is a CDK4 inhibitor with antineoplastic activity .

HY-16297AR

Abemaciclib (Standard)	CDK	Cancer
Abemaciclib (Standard) is the analytical standard of Abemaciclib. This product is intended for research and analytical applications. Abemaciclib (LY2835219) is a selective *CDK4/6* inhibitor with IC₅₀ values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-163272

*GPX4/CDK-IN-1*	Glutathione Peroxidase CDK	Cancer
GPX4/CDK-IN-1 (Compound B9) is a dual inhibitor of *GPX4* and *CDK, with IC₅₀* values of 542.5 nM, 191.2 nM and 68.1 nM for GPX4, CDK4 and CDK6, reapectively. GPX4/CDK-IN-1 shows strong cancer cell growth inhibition in vivo .

HY-101467AR

Trilaciclib (hydrochloride) (Standard)	CDK	Cancer
Trilaciclib (hydrochloride) (Standard) is the analytical standard of Trilaciclib (hydrochloride). This product is intended for research and analytical applications. Trilaciclib hydrochloride (G1T28 hydrochloride) is a *CDK4/6* inhibitor with IC₅₀s of 1 nM and 4 nM for CDK4 and CDK6, respectively .

HY-16297R

Abemaciclib methanesulfonate (Standard)	CDK	Cancer
Abemaciclib (methanesulfonate) (Standard) is the analytical standard of Abemaciclib (methanesulfonate). This product is intended for research and analytical applications. Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective CDK4/6 inhibitor with IC50s of 2 nM and 10 nM for CDK4 and CDK6, respectively .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-103382

Arcyriaflavin A	Infection Alkaloids Structural Classification Microorganisms Classification of Application Fields Source classification Disease Research Fields Indole Alkaloids	Fungal
Arcyriaflavin A is a fungal metabolite obtained from the fungi, Nocardiopsis. Arcyriaflavin A is an inhibitor of CDK4 (IC₅₀ = 140 nM) and CaMKII (IC₅₀ = 25 nM) .

HY-116035

Nimbolide 1 Publications Verification	Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Azadirachta indica A. Juss. Plants Meliaceae Disease Research Fields Cancer	NF-κB CDK Apoptosis
Nimbolide is a triterpene compound that can be isolated from neem (Azadirachta indica), possesses anticancer and antiproliferative activity. Nimbolide induces tumor cell apoptosis by inhibiting NF-κB and *CDK4/CDK6* kinase. Nimbolide suppresses the Wnt, PI3K-Akt, MAPK and JAK-STAT signaling pathways .

HY-18981

Decursin 1 Publications Verification (+)-Decursin	Structural Classification Classification of Application Fields Source classification Coumarins Phenylpropanoids Umbelliferae Plants Inflammation/Immunology Disease Research Fields Echinacea angustifolia DC.	PKC Apoptosis CXCR
Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities ^[4].

HY-N3634

Corylifol C	Structural Classification Leguminosae Source classification Phenols Polyphenols Psoralea corylifolia L. Plants	EGFR TAM Receptor Tie
Corylifol C is a potent protein kinase inhibitor with IC₅₀ valueS of 8.7, 3.0, 2.1, 6.4, 4.5, 6.2, 2.3, 1.2, 5.1 μg/ml for ARK5, Aurora-A, Aurora-B, AXL, B-RAF-VE, CDK4/CycD1, TIE2, EGF-R, EPHB4, respectively .

HY-18981R

Decursin (Standard)	Structural Classification Source classification Coumarins Phenylpropanoids Umbelliferae Plants Echinacea angustifolia DC.	PKC Apoptosis CXCR
Decursin (Standard) is the analytical standard of Decursin. This product is intended for research and analytical applications. Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities ^[3][4].

HY-127057

Lambertianic acid	Pinus lambertiana Douglas Structural Classification Pinaceae Terpenoids Source classification Diterpenoids Plants	Androgen Receptor CDK MDM-2/p53 Apoptosis Caspase PARP Bcl-2 Family
Lambertianic acid is a bioactive diterpene with anti-allergic, antibacterial and anticancer activities. Lambertianic acid decreases androgen receptor protein levels, cellular and secretory levels of prostate-specific antigen. Lambertianic acid also suppresses cell proliferation by inducing G1 arrest, downregulating CDK4/6 and cyclin D1, activating p53, p21 and p27. Lambertianic acid induces Apoptosis and the expression of related proteins, including cleaved caspase-3/9, c-PARP and BAX, and inhibited BCl-2. Lambertianic acid is promising for research of prostate cancer .

HY-N2887

Araliadiol	Structural Classification Natural Products Classification of Application Fields Aralia cordata Thunb. Source classification Plants Disease Research Fields Araliaceae Cancer	Others
Araliadiol is a polyacetylenic compound isolated from the leaves of Aralia cordata Thunb. Araliadiol inhibits MCF-7 cells growth with an IC₅₀ value of 6.41 μg/mL .

HY-133537

Hygrolidin	Infection Structural Classification Microorganisms Antifungal Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Disease Research Anticancer Disease Research Fields	Antibiotic Fungal ADC Cytotoxin
Hygrolidin is a 16-membered macrolide antibiotic produced by Streptomyces hygroscopicus D-1166. Hygrolidin has anti-fungus activity against Valsa ceratosperma. Hygrolidin induces p21 expression and abrogates cell cycle progression at G1 and S phases. Hygrolidin has antitumor activity .

Recombinant Proteins Recommended:

Cyclin-Dependent Kinase 4 (CDK4)

Species:	Human (6)
Tag:	His (4) Tag Free (1) Avi (2) GST (3) Flag (3)
Source:	Sf9 insect cells (5) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P702860

	CDK4 Protein, Human (sf9, His, Avi) CDK4; Cell division protein kinase 4; CMM3; PSK-J3	Human	Sf9 insect cells
	CDK4 protein, acting as a Ser/Thr kinase in the cyclin D-CDK4 complex, critically regulates the G(1)/S transition by phosphorylating and inhibiting RB family members. This activity, specifically hypophosphorylation of RB1 during early G(1) phase, releases E2F and promotes transcription of genes that drive G(1) progression. CDK4 Protein, Human (sf9, His, Avi) is the recombinant human-derived CDK4, expressed by Sf9 insect cells , with N-Avi, N-His labeled tag. The total length of CDK4 Protein, Human (sf9, His, Avi) is 303 a.a.,

HY-P702682

	CDK4-CCND1 Protein, Human (sf9, GST, Flag, His) CDK4; cyclin-dependent kinase 4; PSK J3; cell division protein kinase 4; CMM3; PSK-J3; MGC14458	Human	Sf9 insect cells
	CDK4 protein, acting as a Ser/Thr kinase in the cyclin D-CDK4 complex, critically regulates the G(1)/S transition by phosphorylating and inhibiting RB family members. This activity, specifically hypophosphorylation of RB1 during early G(1) phase, releases E2F and promotes transcription of genes that drive G(1) progression. CDK4-CCND1 Protein, Human (sf9, GST, Flag, His) is the recombinant human-derived CDK4-CCND1, expressed by Sf9 insect cells , with N-His, N-GST, N-Flag labeled tag. ,

HY-P72785

	CDKN2A Protein, Human Cyclin-dependent kinase inhibitor 2A; CDK4I; MTS-1; p16INK4A	Human	E. coli
	CDKN2A Protein, a potent negative regulator of cell proliferation, forms strong interactions with CDK4 and CDK6, hindering their association with cyclins D and retinoblastoma protein phosphorylation. Acting in a heterodimeric manner, predominantly with CDK6, CDKN2A inhibits cyclin D-CDK4 kinase activity and interacts with ISCO2, contributing to its cell cycle regulatory role. CDKN2A Protein, Human is the recombinant human-derived CDKN2A protein, expressed by E. coli , with tag free. The total length of CDKN2A Protein, Human is 155 a.a., with molecular weight of ~19.12 kDa.

HY-P704003

	CDK4 Protein, Human (sf9, His, Flag, Avi) CDK4; Cell division protein kinase 4; CMM3; PSK-J3	Human	Sf9 insect cells

HY-P702684

	CDK4-CCND3 Protein, Human (sf9, GST, His) CDK4; cyclin-dependent kinase 4; PSK J3; cell division protein kinase 4; CMM3; PSK-J3; MGC14458	Human	Sf9 insect cells
	CDK4 protein, acting as a Ser/Thr kinase in the cyclin D-CDK4 complex, critically regulates the G(1)/S transition by phosphorylating and inhibiting RB family members. This activity, specifically hypophosphorylation of RB1 during early G(1) phase, releases E2F and promotes transcription of genes that drive G(1) progression. CDK4-CCND3 Protein, Human (sf9, GST, His) is the recombinant human-derived CDK4-CCND3, expressed by Sf9 insect cells , with N-His, N-GST labeled tag. ,

HY-P702683

	CDK4-CCND2 Protein, Human (sf9, GST, Flag, His) CDK4; cyclin-dependent kinase 4; PSK J3; cell division protein kinase 4; CMM3; PSK-J3; MGC14458	Human	Sf9 insect cells
	CDK4 protein, acting as a Ser/Thr kinase in the cyclin D-CDK4 complex, critically regulates the G(1)/S transition by phosphorylating and inhibiting RB family members. This activity, specifically hypophosphorylation of RB1 during early G(1) phase, releases E2F and promotes transcription of genes that drive G(1) progression. CDK4-CCND2 Protein, Human (sf9, GST, Flag, His) is the recombinant human-derived CDK4-CCND2, expressed by Sf9 insect cells , with N-His, N-GST, N-Flag labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-16297AS

Abemaciclib-d8
Abemaciclib-d₈ is the deuterium labeled Abemaciclib. Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-50767S

Palbociclib-d8
Palbociclib-d₈ is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].

HY-129336S

Abemaciclib metabolite M20-d8
Abemaciclib metabolite M20-d₈ is the deuterium labeled Abemaciclib metabolite M20. Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4/6 inhibitor[1].

HY-15777AS

Ribociclib-d6 hydrochloride
Ribociclib-d₆ (hydrochloride) is a deuterium labeled Ribociclib. Ribociclib is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex[1].

HY-15777S1

Ribociclib-d8
Ribociclib-d₈ is the deuterium labeled Ribociclib[1]. Ribociclib (LEE01) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex[2].

HY-128669S

Abemaciclib metabolite M2-d6
Abemaciclib metabolite M2-d₆ is the deuterium labeled Abemaciclib metabolite M2. Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC50s in the range of 1-3 nM. Anti-cancer activity[1][2].

HY-126534S

Abemaciclib metabolite M18-d8
Abemaciclib metabolite M18-d₈ is the deuterium labeled Abemaciclib metabolite M18. Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 and a CRBN ligand have been used to design PROTAC CDK4/6 degrader[1][2].

HY-15777S

Ribociclib-d6
Ribociclib-d₆ is a deuterium labeled Ribociclib. Ribociclib is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex[1].

HY-50767S1

Palbociclib-d4 hydrochloride
Palbociclib-d₄ (hydrochloride) is the deuterium labeled Palbociclib hydrochloride. Palbociclib (PD 0332991) is a selective CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].

HY-W654305

Palbociclib-d4

Palbociclib-d₄ is deuterium labeled Palbociclib. Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma ^[4].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80077

	Cdk4 Antibody	WB, ICC/IF, IHC-P, IP	Human, Mouse
	Cdk4 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 34 kDa, targeting to Cdk4. It can be used for WB,ICC/IF,IHC-P,IP assays with tag free, in the background of Human, Mouse.

HY-P80992

	CDKN2A/p16INK4a Antibody ARF antibody; CDK4 inhibitor p16 INK4 antibody; CDK4I antibody; CDKN2 antibody; CDKN2A antibody; Cell cycle negative regulator beta antibody; CMM2 antibody; INK4 antibody; INK4a antibody; Melanoma p16 inhibits CDK4 antibody; MLM antibody; MTS1 antibody; Multiple tumor suppressor 1 antibody; p16 antibody; p16 INK4a antibody; p16INK4a antibody; p19 antibody; P19ARF antibody; TP16 antibody;	WB, IHC-P	Human
	CDKN2A/p16INK4a Antibody is an unconjugated, approximately 16 kDa, rabbit-derived, anti-CDKN2A/p16INK4a monoclonal antibody. CDKN2A/p16INK4a Antibody can be used for: WB, IHC-P expriments in human background without labeling.

HY-P80615

	CDKN2A/p16INK4a Antibody (YA508) CDK4 inhibitor p16 INK4 antibody; CDK4I antibody; CDKN2 antibody; CDKN2A antibody; Cell cycle negative regulator beta antibody; CMM2 antibody; Cyclin dependent kinase 4 inhibitor A antibody; Cyclin dependent kinase inhibitor 2A (melanoma p16 inhibits CDK4) antibody; Cyclin Dependent Kinase Inhibitor 2A antibody; Cyclin dependent kinase inhibitor 2A isoform 4 antibody; Cyclin dependent kinase inhibitor 2A isoforms 1/2/3 antibody; Cyclin dependent kinase inhibitor p16 antibody; INK4 antibody; INK4A antibody; MLM antibody; MTS1 antibody; Multiple tumor suppressor 1 antibody; p14 antibody; p16 antibody; P16INK4 antibody; p16INK4a antibody; p19 antibody; p19Arf antibody; TP16 antibody	WB, IP	Human, Mouse
	CDKN2A Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 17 kDa, targeting to CDKN2A. It can be used for WB,IP assays with tag free, in the background of Human, Mouse.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-148213

CDK2/4/6-IN-1		Alkynes
CDK2/4/6-IN-1(example 29) is a *CDK2/4/6* inhibitor with IC₅₀ values of 2.5, 23.7 and 44.3 nM for CDK2, CDK4 and CDK6, respectively. CDK2/4/6-IN-1 can be used in cancer research . CDK2/4/6-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks